Skip to Content

Exploring the public health and equalities implications of GLP-1 obesity medications

Nov 2026

GLP-1 medications have rapidly emerged as a significant clinical and cultural phenomenon, generating considerable public interest, media attention and debate. Alongside growing excitement about their potential, public discussion has often been characterised by competing claims, misinformation and polarised perspectives. Against this backdrop, the Glasgow Centre for Population Health has undertaken a multidisciplinary scoping review of the evidence, seeking to move beyond the headlines and provide a balanced, critical and accessible assessment of what is currently known, what remains uncertain and what these developments might mean for population health and society.

While much of the discussion surrounding GLP-1 medications has understandably focused on their clinical effectiveness, their implications extend far beyond individual treatment and weight loss. Their expanding use raises fundamental questions about prevention, health inequalities, equitable access, healthcare systems, public spending and the wider social, economic and commercial determinants of health. Understanding these dimensions is essential if the potential benefits of GLP-1 medications are to be realised fairly and sustainably.

 A public health and equalities perspective allows us to consider not only what these medications can achieve for individuals, but also who can access and benefit from them, how their use may interact with existing inequalities, and what their growing availability could mean for wider approaches to improving population health. This perspective is particularly important in Scotland, where obesity and its associated health consequences are deeply patterned by socioeconomic circumstances and wider structural inequalities.

To support accessibility, encourage informed discussion and maximise the report's relevance and influence across research, policy, practice and wider public audiences, the scoping review is structured around ten guiding questions. These questions bring together evidence from clinical, public health, social, economic and policy perspectives, providing a framework for examining the opportunities, complexities and uncertainties surrounding GLP-1 medications. Rather than presenting a definitive account of a rapidly evolving field, the review aims to stimulate critical reflection, identify important evidence gaps and contribute to more informed, proportionate and equitable approaches to policy and practice.

Ten guiding questions

  1. How effective are GLP-1 medications in achieving clinically meaningful weight loss?
  2. Can GLP-1 medications be considered an effective form of prevention within public health?
  3. What are the safety considerations, side-effects and potential harms of GLP-1 medications?
  4. Is weight loss achieved through GLP-1 medications sustainable?
  5. Are GLP-1 medications cost-effective at a population level?
  6. What are the possible impacts of GLP-1 medications on health inequalities?
  7. What are the implications of online access, private prescribing and unregulated use of GLP-1 medications?
  8. What are the consequences of GLP-1 medications for traditional lifestyle-based health improvement approaches?
  9. What are the wider system repercussions of GLP-1 usage, including food systems, healthcare and social prescribing?
  10. How do GLP-1 medications align with public health policy and service reform agendas in Scotland?

Exploring the public health and equalities implications of GLP-1 obesity medications

pdf | 2.17MB

Download

Back to

Publications and resources